Arbutus Biopharma Future Growth
Future criteria checks 2/6
Arbutus Biopharma is forecast to grow earnings and revenue by 11.7% and 44.2% per annum respectively while EPS is expected to grow by 14.5% per annum.
Key information
11.7%
Earnings growth rate
14.5%
EPS growth rate
| Biotechs earnings growth | 42.4% |
| Revenue growth rate | 44.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 8 | -81 | N/A | N/A | 1 |
| 12/31/2025 | 5 | -69 | N/A | N/A | 5 |
| 12/31/2024 | 6 | -73 | N/A | N/A | 5 |
| 9/30/2024 | 7 | -77 | -72 | -72 | N/A |
| 6/30/2024 | 10 | -77 | -73 | -73 | N/A |
| 3/31/2024 | 13 | -74 | -79 | -78 | N/A |
| 12/31/2023 | 18 | -73 | -87 | -86 | N/A |
| 9/30/2023 | 22 | -75 | -87 | -86 | N/A |
| 6/30/2023 | 24 | -73 | -84 | -83 | N/A |
| 3/31/2023 | 33 | -70 | -84 | -83 | N/A |
| 12/31/2022 | 39 | -69 | -36 | -35 | N/A |
| 9/30/2022 | 36 | -69 | -38 | -38 | N/A |
| 6/30/2022 | 33 | -76 | -36 | -35 | N/A |
| 3/31/2022 | 21 | -85 | -30 | -29 | N/A |
| 12/31/2021 | 11 | -88 | -68 | -68 | N/A |
| 9/30/2021 | 10 | -87 | -64 | -63 | N/A |
| 6/30/2021 | 8 | -84 | -60 | -59 | N/A |
| 3/31/2021 | 8 | -79 | -54 | -54 | N/A |
| 12/31/2020 | 7 | -76 | -52 | -51 | N/A |
| 9/30/2020 | 6 | -83 | -50 | -50 | N/A |
| 6/30/2020 | 8 | -147 | -61 | -61 | N/A |
| 3/31/2020 | 7 | -156 | -70 | -70 | N/A |
| 12/31/2019 | 6 | -165 | -72 | -71 | N/A |
| 9/30/2019 | 6 | -158 | -75 | -75 | N/A |
| 6/30/2019 | 5 | -100 | -65 | -64 | N/A |
| 3/31/2019 | 5 | -73 | -65 | -64 | N/A |
| 12/31/2018 | 6 | -67 | -69 | -68 | N/A |
| 9/30/2018 | 7 | -83 | -62 | -61 | N/A |
| 6/30/2018 | 12 | -68 | N/A | -64 | N/A |
| 3/31/2018 | 12 | -86 | N/A | -51 | N/A |
| 12/31/2017 | 11 | -85 | N/A | -49 | N/A |
| 9/30/2017 | 8 | -267 | N/A | -53 | N/A |
| 6/30/2017 | 2 | -275 | N/A | -52 | N/A |
| 3/31/2017 | 1 | -387 | N/A | -64 | N/A |
| 12/31/2016 | 1 | -384 | N/A | -58 | N/A |
| 9/30/2016 | 14 | -171 | N/A | -60 | N/A |
| 6/30/2016 | 18 | -180 | N/A | -47 | N/A |
| 3/31/2016 | 21 | -65 | N/A | -48 | N/A |
| 12/31/2015 | 23 | -63 | N/A | -56 | N/A |
| 9/30/2015 | 17 | -62 | N/A | -45 | N/A |
| 6/30/2015 | 17 | -42 | N/A | -49 | N/A |
| 3/31/2015 | 15 | -33 | N/A | -39 | N/A |
| 12/31/2014 | 15 | -39 | N/A | -12 | N/A |
| 9/30/2014 | 18 | -35 | N/A | -3 | N/A |
| 6/30/2014 | 17 | -33 | N/A | 0 | N/A |
| 3/31/2014 | 18 | -30 | N/A | 5 | N/A |
| 12/31/2013 | 15 | -14 | N/A | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: I9DN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: I9DN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: I9DN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: I9DN's revenue (44.2% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: I9DN's revenue (44.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if I9DN's Return on Equity is forecast to be high in 3 years time